40 results
8-K
EX-10.1
HEPA
Hepion Pharmaceuticals Inc
2 Oct 23
Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules
6:29pm
to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company's knowledge, threatened, action (including any lawsuit
424B5
HEPA
Hepion Pharmaceuticals Inc
2 Oct 23
Prospectus supplement for primary offering
4:52pm
stockholders from bringing a lawsuit against directors for breach of their fiduciary duty. These provisions may also have the effect of reducing … Certificate of Incorporation and by-laws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duty
424B5
HEPA
Hepion Pharmaceuticals Inc
21 Jul 23
Prospectus supplement for primary offering
4:39pm
of Incorporation and by-laws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duty. These provisions may
8-K
EX-10.1
HEPA
Hepion Pharmaceuticals Inc
8 Nov 22
Hepion Pharmaceuticals Announces Pricing of $20.0 Million Private Placement of Convertible Redeemable Preferred Stock
8:41pm
or, to the Company’s knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint
424B5
8q85ee wr
16 Feb 21
Prospectus supplement for primary offering
5:11pm
424B5
km4xdg1xcvlk n9wcqg2
16 Feb 21
Prospectus supplement for primary offering
6:03am
S-8
4soqb3j
19 Jan 21
Registration of securities for employees
12:00am
424B5
rv5d4b 5l0leuffo8
26 Mar 20
Prospectus supplement for primary offering
9:33pm
424B5
0ew3xp30b3ogy97eyr
12 Feb 20
Prospectus supplement for primary offering
9:05am
S-8
t8q qd2vdmypx
21 Oct 19
Registration of securities for employees
4:26pm